Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631185 | 0.82 | DGAT1 (0.34) | NPC1MAPTDGAT1 | |
| SCHEMBL26093067 | 0.81 | DGAT1 (0.36) | NPC1MAPTDGAT1 | |
| SCHEMBL4177207 | 0.77 | NPC1 (0.35) | NPC1MAPTDGAT1 | |
| Potassium Ion SCHEMBL4187966 | 0.75 | NPC1 (0.34) | NPC1MAPTDGAT1 | |
| SCHEMBL4182056 | 0.74 | ADORA3 (0.37) | MAPTDGAT1 | |
| SCHEMBL3033883 | 0.72 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL3032289 | 0.72 | MAPT (0.31) | MAPT | |
| SCHEMBL13871295 | 0.70 | F2RL1 (0.34) | NPC1DGAT1 | |
| SCHEMBL25586533 | 0.69 | DGAT1 (0.36) | NPC1MAPTDGAT1 | |
| SCHEMBL9958624 | 0.69 | NPC1 (0.33) | NPC1MAPTDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452996-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-9221797-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | NPC1 4455/4885MAPT 172/4885DGAT1 3866/4885 |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | NPC1 4455/4885MAPT 172/4885DGAT1 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.